Antiviral therapy for chronic hepatitis B in pregnancy

Seminars in Liver Disease

Volumn 33, Issue 2, 2013, Pages 138-146

  Pan, Calvin Q ^a   Lee, Hannah M ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiviral treatment; drug safety; fetal exposure; hepatitis B in pregnancy; vertical transmission

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMALE; FIRST TRIMESTER PREGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; MIXED INFECTION; MOTHER; PATIENT MONITORING; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIRAL CLEARANCE; VIREMIA; VIRUS REACTIVATION;

ALGORITHMS; ANTIVIRAL AGENTS; DECISION SUPPORT TECHNIQUES; FEMALE; FETUS; GESTATIONAL AGE; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84878855035     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1345718     Document Type: Article

References (49)

1. World Health Organization Hepatitis B Fact sheet, July 2012. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed November 1, 2012
2. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis: 2007; 11 4 945 963 (Pubitemid 350019024)
3. Weinbaum C. M., Williams I., Mast E. E., et al. Centers for Disease Control and Prevention (CDC) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep: 2008; 57 RR-8 1 20
4. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol: 2012; 57 1 167 185
5. Lok A. SF, McMahon B. J. Chronic hepatitis B: update 2009. Hepatology: 2009; 50 3 661 662
6. Tong M. J., Pan C. Q., Hann H. W., et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci: 2011; 56 11 3143 3162
7. Lao T. T., Chan B. C., Leung W. C., Ho L. F., Tse K. Y. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol: 2007; 47 1 46 50 (Pubitemid 46830719)
8. Towers C. V., Asrat T., Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol: 2001; 184 7 1514 1518, discussion 1518-1520
9. Tse K. Y., Ho L. F., Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol: 2005; 43 5 771 775 (Pubitemid 41414501)
10. Reddick K. L., Jhaveri R., Gandhi M., James A. H., Swamy G. K. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat: 2011; 18 7 e394 e398
11. Safir A., Levy A., Sikuler E., Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int: 2010; 30 5 765 770
12. Wong S., Chan L. Y., Yu V., Ho L. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol: 1999; 16 9 485 488 (Pubitemid 30196916)
13. Lobstein S., Faber R., Tillmann H. L. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion: 2011; 83 1-2 76 82
14. Connell L. E., Salihu H. M., Salemi J. L., August E. M., Weldeselasse H., Mbah A. K. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int: 2011; 31 8 1163 1170
15. Terazawa S., Kojima M., Yamanaka T., et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res: 1991; 29 1 5 9
16. Tan H. H., Lui H. F., Chow W. C. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int: 2008; 2 3 370 375
17. Söderström A., Norkrans G., Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis: 2003; 35 11-12 814 819 (Pubitemid 38028916)
18. Yang Y. B., Li X. M., Shi Z. J., Ma L. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J Gastroenterol: 2004; 10 15 2305 2306 (Pubitemid 39144993)
19. ter Borg M. J., Leemans W. F., de Man R. A., Janssen H. L. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat: 2008; 15 1 37 41 (Pubitemid 350243581)
20. Lin H. H., Wu W. Y., Kao J. H., Chen D. S. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol: 2006; 21 3 605 609
21. Rawal B. K., Parida S., Watkins R. P., Ghosh P., Smith H. Symptomatic reactivation of hepatitis B in pregnancy. Lancet: 1991; 337 8737 364
22. Nguyen G., Garcia R. T., Nguyen N., Trinh H., Keeffe E. B., Nguyen M. H. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther: 2009; 29 7 755 764
23. Xu W. M., Cui Y. T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat: 2009; 16 2 94 103
24. Zou H., Chen Y., Duan Z., Zhang H., Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat: 2012; 19 2 e18 e25
25. Xu D. Z., Yan Y. P., Choi B. C., et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol: 2002; 67 1 20 26 (Pubitemid 34260071)
26. Wiseman E., Fraser M. A., Holden S., et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust: 2009; 190 9 489 492
27. Burk R. D., Hwang L. Y., Ho G. Y., Shafritz D. A., Beasley R. P. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis: 1994; 170 6 1418 1423 (Pubitemid 24369900)
28. Pan C. Q., Duan Z. P., Bhamidimarri K. R., et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol: 2012; 10 5 452 459
29. Han G. R., Cao M. K., Zhao W., et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol: 2011; 55 6 1215 1221
30. Pan C. Q., Han G. R., Jiang H. X., et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol: 2012; 10 5 520 526
31. Feibus K. B. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol: 2008; 4 4 284 288
32. Antiviral Pregnancy Registry (APR) Antiviral Pregnancy Registry Interim Report 1, January 1989 through 31 January 2012. Available at: http://APregistry.com 2012. Accessed November 1, 2012
33. Pan C., Zhang H., Pang Q., et al. Real world data on the efficacy and safety of telbivudine or lamivudine use in late pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infants. Hepatology: 2012; 56 S1 368A
34. Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy. Ann Trop Paediatr: 2009; 29 4 257 261
35. Alimenti A., Burdge D. R., Ogilvie G. S., Money D. M., Forbes J. C. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J: 2003; 22 9 782 789
36. Gibb D. M., Kizito H., Russell E. C., et al. DART trial team Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med: 2012; 9 5 e1001217
37. Viganò A., Mora S., Giacomet V., et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther: 2011; 16 8 1259 1266
38. Siberry G. K., Williams P. L., Mendez H., et al. Pediatric HIV/AIDS Cohort Study (PHACS) Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS: 2012; 26 9 1151 1159
39. Han G. R., Jiang X. H., Zhao W., et al. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission of chronic hepatitis B in highly viremic mothers. Hepatology: 2011; 54 S4 479A
40. Pan C. Q., Mi L. J., Bunchorntavakul C., et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci: 2012; 57 9 2423 2429
41. U.S. National Institutes of Health ClinicalTrials.gov. Available at: http://clinicaltrialsgov/show/NCT01488526. Accessed November 1, 2012
42. Keeffe E. B., Dieterich D. T., Han S. H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol: 2008; 6 12 1315 1341, quiz 1286
43. Garg H., Sarin S. K., Kumar M., Garg V., Sharma B. C., Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology: 2011; 53 3 774 780
44. Shaheen A. A., Myers R. P. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int: 2010; 30 2 275 283
45. Nie R., Jin L., Zhang H., Xu B., Chen W., Zhu G. Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. Fertil Steril: 2011; 95 5 1667 1671
46. Wong V. C., Lee A. K., Ip H. M. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol: 1980; 87 11 958 965 (Pubitemid 11250491)
47. Beasley R. P., Stevens C. E., Shiao I. S., Meng H. C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet: 1975; 2 7938 740 741
48. Hill J. B., Sheffield J. S., Kim M. J., Alexander J. M., Sercely B., Wendel G. D. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol: 2002; 99 6 1049 1052 (Pubitemid 34621230)
49. Van Rompay K. K., Hamilton M., Kearney B., Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother: 2005; 49 5 2093 2094 (Pubitemid 40631628)